HUP0401523A3 - Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them - Google Patents

Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them

Info

Publication number
HUP0401523A3
HUP0401523A3 HU0401523A HUP0401523A HUP0401523A3 HU P0401523 A3 HUP0401523 A3 HU P0401523A3 HU 0401523 A HU0401523 A HU 0401523A HU P0401523 A HUP0401523 A HU P0401523A HU P0401523 A3 HUP0401523 A3 HU P0401523A3
Authority
HU
Hungary
Prior art keywords
indole
producing
pharmaceutical compositions
compositions containing
carboxamide derivatives
Prior art date
Application number
HU0401523A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Richter Gedeon Vegyeszet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Vegyeszet filed Critical Richter Gedeon Vegyeszet
Priority to HU0401523A priority Critical patent/HUP0401523A3/hu
Publication of HU0401523D0 publication Critical patent/HU0401523D0/hu
Priority to BRPI0513932-5A priority patent/BRPI0513932A/pt
Priority to JP2007523161A priority patent/JP2008508248A/ja
Priority to EA200700365A priority patent/EA009981B1/ru
Priority to GEAP20059893A priority patent/GEP20094606B/en
Priority to US11/658,787 priority patent/US20090048303A1/en
Priority to AT05764412T priority patent/ATE427299T1/de
Priority to AU2005266160A priority patent/AU2005266160A1/en
Priority to KR1020077000263A priority patent/KR20070038502A/ko
Priority to MX2007001052A priority patent/MX2007001052A/es
Priority to PCT/HU2005/000078 priority patent/WO2006010965A1/en
Priority to CNA2005800247658A priority patent/CN1989103A/zh
Priority to AP2006003840A priority patent/AP2006003840A0/xx
Priority to DE602005013675T priority patent/DE602005013675D1/de
Priority to EP05764412A priority patent/EP1773770B1/en
Priority to CA002574155A priority patent/CA2574155A1/en
Priority to IL179485A priority patent/IL179485A0/en
Publication of HUP0401523A2 publication Critical patent/HUP0401523A2/hu
Priority to ZA200700325A priority patent/ZA200700325B/en
Priority to TNP2007000016A priority patent/TNSN07016A1/en
Priority to MA29702A priority patent/MA28815B1/fr
Priority to NO20071109A priority patent/NO20071109L/no
Publication of HUP0401523A3 publication Critical patent/HUP0401523A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
HU0401523A 2004-07-29 2004-07-29 Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them HUP0401523A3 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
HU0401523A HUP0401523A3 (en) 2004-07-29 2004-07-29 Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
CA002574155A CA2574155A1 (en) 2004-07-29 2005-07-21 Indole-2 -carboxamidine derivatives as nmda receptor antagonists
PCT/HU2005/000078 WO2006010965A1 (en) 2004-07-29 2005-07-21 Indole-2 -carboxamidine derivatives as nmda receptor antagonists
AP2006003840A AP2006003840A0 (en) 2004-07-29 2005-07-21 Indole-2-carboxamidine derivatives as NMDA receptor antagonists
EA200700365A EA009981B1 (ru) 2004-07-29 2005-07-21 Производные индол-2-карбоксамидина как антагонисты nmda рецептора
GEAP20059893A GEP20094606B (en) 2004-07-29 2005-07-21 Indole-2 -carboxamidine derivatives as nmda receptor antagonists
US11/658,787 US20090048303A1 (en) 2004-07-29 2005-07-21 Indole-2-carboxamidine derivatives as nmda receptor antago
AT05764412T ATE427299T1 (de) 2004-07-29 2005-07-21 Indol-2-carboxamidin-derivate als antagonisten der nmda-rezeptoren
AU2005266160A AU2005266160A1 (en) 2004-07-29 2005-07-21 Indole-2 -carboxamidine derivatives as NMDA receptor antagonists
KR1020077000263A KR20070038502A (ko) 2004-07-29 2005-07-21 Ｎｍｄａ 수용체 길항물질인 인돌-2-카르복사미딘 유도체
MX2007001052A MX2007001052A (es) 2004-07-29 2005-07-21 Nuevos derivados de indol-2-carboxamidina como antagonistas del receptor nmda.
BRPI0513932-5A BRPI0513932A (pt) 2004-07-29 2005-07-21 derivados de indol-2-carboxamidina como antagonistas de receptores de nmda
CNA2005800247658A CN1989103A (zh) 2004-07-29 2005-07-21 作为nmda受体拮抗剂的吲哚－2－甲脒衍生物
JP2007523161A JP2008508248A (ja) 2004-07-29 2005-07-21 Ｎｍｄａ受容体アンタゴニストとしてのインドール−２−カルボキサミジン誘導体
DE602005013675T DE602005013675D1 (de) 2004-07-29 2005-07-21 Indol-2-carboxamidin-derivate als antagonisten der nmda-rezeptoren
EP05764412A EP1773770B1 (en) 2004-07-29 2005-07-21 Indole-2-carboxamidine derivatives as nmda receptor antagonists
IL179485A IL179485A0 (en) 2004-07-29 2006-11-22 Indole-2 carboxamidine derivatives as nmda receptor antagonists
ZA200700325A ZA200700325B (en) 2004-07-29 2007-01-11 Indole-2-carboxamidine derivatives as NMDA receptor antagonists
TNP2007000016A TNSN07016A1 (en) 2004-07-29 2007-01-17 Indole-2-carboxamidine derivatives as nmda receptor antagonists
MA29702A MA28815B1 (fr) 2004-07-29 2007-02-22 Derives de indole-2-carboxamidine utilises comme antagonistes du recepteur nmda
NO20071109A NO20071109L (no) 2004-07-29 2007-02-27 Indol-2-karboksamidinderivater som NMDA-reseptorantagonister

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0401523A HUP0401523A3 (en) 2004-07-29 2004-07-29 Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them

Publications (3)

Publication Number Publication Date
HU0401523D0 HU0401523D0 (en) 2004-09-28
HUP0401523A2 HUP0401523A2 (en) 2006-11-28
HUP0401523A3 true HUP0401523A3 (en) 2007-05-02

Family

ID=89985408

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401523A HUP0401523A3 (en) 2004-07-29 2004-07-29 Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them

Country Status (21)

Country Link
US (1) US20090048303A1 (enExample)
EP (1) EP1773770B1 (enExample)
JP (1) JP2008508248A (enExample)
KR (1) KR20070038502A (enExample)
CN (1) CN1989103A (enExample)
AP (1) AP2006003840A0 (enExample)
AT (1) ATE427299T1 (enExample)
AU (1) AU2005266160A1 (enExample)
BR (1) BRPI0513932A (enExample)
CA (1) CA2574155A1 (enExample)
DE (1) DE602005013675D1 (enExample)
EA (1) EA009981B1 (enExample)
GE (1) GEP20094606B (enExample)
HU (1) HUP0401523A3 (enExample)
IL (1) IL179485A0 (enExample)
MA (1) MA28815B1 (enExample)
MX (1) MX2007001052A (enExample)
NO (1) NO20071109L (enExample)
TN (1) TNSN07016A1 (enExample)
WO (1) WO2006010965A1 (enExample)
ZA (1) ZA200700325B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
EP2091948B1 (en) 2006-11-30 2012-04-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
KR20120123089A (ko) 2010-02-16 2012-11-07 화이자 인코포레이티드 5-ＨＴ₄ 수용체의 부분 효능제인 (Ｒ)-4-((4-((4-(테트라히드로푸란-3-일옥시)벤조［ｄ］이속사졸-3-일옥시)메틸)피페리딘-1-일)메틸)테트라히드로-2Ｈ-피란-4-올
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
BR112012022478B1 (pt) 2010-03-10 2021-09-21 Probiodrug Ag Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
BR112013012309A2 (pt) * 2010-11-18 2016-08-23 Univ Yale composto, composição, métodos de tratamento e usos de um composto
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
WO2013175211A1 (en) * 2012-05-22 2013-11-28 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
WO2019022179A1 (ja) * 2017-07-28 2019-01-31 武田薬品工業株式会社 複素環化合物
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726388D0 (en) * 1997-12-12 1998-02-11 Cerebrus Ltd Chemical compounds
US6376530B1 (en) * 1999-05-10 2002-04-23 Merck & Co., Inc. Cyclic amidines useful as NMDA NR2B antagonists
US6319944B1 (en) * 1999-05-10 2001-11-20 Merck & Co., Inc. Aryl amidines, compositions containing such compounds and methods of use
GB0015488D0 (en) * 2000-06-23 2000-08-16 Merck Sharp & Dohme Therapeutic agents
HU227197B1 (en) * 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
JP2004253425A (ja) * 2003-02-18 2004-09-09 Tdk Corp 積層コンデンサ

Also Published As

Publication number Publication date
EP1773770A1 (en) 2007-04-18
EP1773770B1 (en) 2009-04-01
GEP20094606B (en) 2009-02-10
NO20071109L (no) 2007-02-27
WO2006010965A1 (en) 2006-02-02
AU2005266160A1 (en) 2006-02-02
DE602005013675D1 (de) 2009-05-14
CN1989103A (zh) 2007-06-27
JP2008508248A (ja) 2008-03-21
MA28815B1 (fr) 2007-08-01
IL179485A0 (en) 2007-05-15
MX2007001052A (es) 2007-04-16
US20090048303A1 (en) 2009-02-19
KR20070038502A (ko) 2007-04-10
HU0401523D0 (en) 2004-09-28
TNSN07016A1 (en) 2008-06-02
CA2574155A1 (en) 2006-02-02
ZA200700325B (en) 2008-05-28
AP2006003840A0 (en) 2006-12-31
EA200700365A1 (ru) 2007-06-29
BRPI0513932A (pt) 2008-05-20
ATE427299T1 (de) 2009-04-15
HUP0401523A2 (en) 2006-11-28
EA009981B1 (ru) 2008-04-28

Similar Documents

Publication Publication Date Title
IL185353A0 (en) Azabicycloalkane derivatives , pharmaceutical compositions containing the same and methods for the preparation thereof
HUP0500170A3 (en) Piperazine derivatives, process for producing them and pharmaceutical compositions containing them
IL193772A0 (en) 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same
IL210756A0 (en) Carbostyril compound, process for their preparation and pharmaceutical compositions containing them
PL2036892T3 (pl) Pochodne 1,2,4,5-tetrahydro-3H-benzazepin, sposób ich wytwarzania i zawierające je kompozycje farmaceutyczne
IL187713A0 (en) 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof
SI1752443T1 (sl) Nova kristalinična oblika V agomelatina, postopek za njeno pripravo in farmacevtski sestavki, ki jo vsebujejo
PL1902034T3 (pl) Nowe ligandy receptorów kanabinoidowych, kompozycja farmaceutyczna je zawierająca oraz proces ich wytwarzania
HUP0401523A3 (en) Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
HUP0401522A2 (en) New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
PL2210872T3 (pl) Nowa postać krystaliczna III agomelatyny, sposób jej wytwarzania i kompozycje farmaceutyczne ją zawierające
PL1720544T3 (pl) Nowe pochodne azabicykliczne, sposób ich wytwarzania i zawierające je kompozycje farmaceutyczne
IL186062A (en) Indanyl-piperazine derivatives, method for preparing same and pharmaceutical compositions containing same
TWI315305B (en) Piperidin-4-yl-amide derivatives,pharmaceutical compositions comprising the same,process for preparing the same and the use thereof
IL190596A0 (en) 9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
ZA200902414B (en) Indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them
ZA200806399B (en) Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them
SI1655030T1 (sl) Derivati benzotiadiazina, postopek za pripravo le-teh in farmacevtski sestavki, ki jih vsebujejo
ZA200902413B (en) Novel indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them
IL189177A0 (en) Process for producing carcosporamide and pharmaceutical compositions containing cercosporamide
IL183438A0 (en) Substituted indoles, compositions containing them, method for the production thereof and their use
ZA200711106B (en) Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
SI1748043T1 (sl) Polisubstituirane spojine 1,1-piridiniloksiciklopropanaminov, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
HUP0302440A3 (en) Aminoquinoline derivatives, process for producing them and pharmaceutical compositions containing them
DE602006003956D1 (en) Novel polysubstituted 1,1-pyridinylaminocyclopropanamine derivatives, processes for their preparation and pharmaceutical composition containing them

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: RICHTER GEDEON NYRT., HU

Free format text: FORMER OWNER(S): RICHTER GEDEON VEGYESZETI GYAR RT., HU

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished